Joel Neoh joins NASDAQ-listed genomics and precision oncology company, Prenetics as MD of its consumer arm, CircleDNA

• Tasked to expand CircleDNA into leading consumer preventive healthcare platform
• Intrigued by mission of Prenetics & CircleDNA, immense potential to positively affect lives

Prenetics Global Ltd a Nasdaq listed genomics and precision oncology company, has announced the appointment of Joel Neoh (pic) to head up CircleDNA as Managing Director. Additionally, Joel will be taking on the role of Chief Consumer Officer of the group, to further expand CircleDNA into a leading consumer preventive healthcare platform.

Joel’s appointment comes as Prenetics is forging ahead to reinvent the preventive healthcare landscape, with a focus on harmonizing consumer health and genetics, breakthrough technology for early cancer detection, and targeted therapy for cancer treatment. As part of the company’s transformation, it seeks to significantly expand into new verticals and introduce new personalized healthcare offerings to consumers within CircleDNA.

"In all honesty, after my recent departure from Fave, I had planned an extended vacation and even organised travel plans through mid-2024. Yet, life often surprises us. Casual chats with Danny Yeung (CEO of Prenetics), a close friend of over ten years, took an unexpected turn. The mission of Prenetics and CircleDNA, dedicated to providing an expansive healthcare ecosystem, thoroughly intrigued me. Realising the immense potential for us to positively affect people's lives, helping them to live healthier and happier, I made a conscious decision to shelve the vacation and join the cause," shared Joel.

"As an entrepreneur who has received significant support, particularly in Southeast Asia, I feel a strong desire to contribute back to the community by promoting health and emphasising the importance of preventive care," Joel added.

With over 300,000 CircleDNA consumers already in place, Joel expressed confidence in expanding this base to millions worldwide.

“I'm learning an incredible amount each day about genetics, healthcare, new cancer technology, and the wealth of invaluable insights offered by our scientist community has been eye-opening. It's been a truly remarkable experience that I'm eager to share more about in due time."

Danny (pic) said, "The healthcare landscape is undeniably complex, but I have unwavering confidence that with Joel leading CircleDNA, we are poised for significant growth while positively impacting the lives of millions across the globe. Moreover, our clinical genomics business has made remarkable strides, as evidenced by being the first Asia-based company to receive FDA clearance for a comprehensive Genomic Profiling Test. Given that this year is marked by transformation, rest assured that there are more groundbreaking developments on the horizon."

The rising affluence in Southeast Asia is steering consumer attention towards health consciousness in the post-COVID era, consequently fueling the company's further expansion in this region.

CircleDNA is also broadening its reach into the domain of preventive and personalized healthcare management. This expanded direction will include local country partnerships to incorporate a wide spectrum of services such as blood tests, telehealth services, personalized supplements and online to offline healthcare services. These new products and services are scheduled to roll out over the next 12 months.